New delivery systems may revive potential of peptide drugs

01/14/2005 |

New therapeutic approaches, plus the potential of the drugs themselves, may mean a renaissance in peptide drugs, according to a new report. Approval of new peptide-based drug products, such as Roche's HIV treatment Fuzeon, is increasing interest among pharmaceutical companies. In Europe, as many as six peptide-based products are on the market, with 100 in the clinical stage and 150 in advanced preclinical phases.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA